All In Biotech

Drug Trial Radar · NCT05267886

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 346 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

346

Planned (sponsor's estimate)

Start

Mar 5, 2022

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Ottawa Heart Institute Research CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.

Conditions

  • Shock, Cardiogenic

Interventions

  • DobutamineDrug

    Dobutamine administered according to its clinical dose stage for cardiogenic shock

  • MilrinoneDrug

    Milrinone administered according to its clinical dose stage for cardiogenic shock

  • Normal SalineDrug

    Normal saline running at a standardized rate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary composite outcomeTime frame: Through duration of hospitalization, up to 12 weeks following admission

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota · Not yet recruiting

  • Hamilton Health Sciences

    Hamilton, Ontario, Canada · Recruiting

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.